Zydus Revolutionizes Cancer Care with Tishtha Biosimilar Launch

In an innovative move set to redefine cancer treatment accessibility, Zydus Lifesciences has launched Tishtha, the world’s first Nivolumab biosimilar, in India.

This innovative breakthrough is a significant step in the field of immuno-oncology, as it would give cancer patients an inexpensive and dependable alternative to the expensive reference product.

Tishsta is a major innovation in the cancerous treatment because it provides economical treatment methods of immunotherapy that cost about a quarter of the reference price. Its two strengths of 100mg and 40mg are the best dose optimality of the drug and minimum wastage of the drug which further reduces costs of treatment with regard to the patients.

Also Read: Engineering Leadership Across India's Mining & Infra Value Chain

There is also a consistency in availability through this initiative because the biosimilar is produced and created in India and this factors in the issues of drug availability that are commonly experienced in emerging markets.

The introduction of Tishtha by Zydus as a response to patient-centric innovation means that healthcare systems have the opportunity to offer more sustainable and accessible cancer care to their patients. The introduction also supports the commitment of the company to biologics and immuno-oncology, which is a milestone towards enhancing the general affordability and accessibility of life-saving cancer therapies.

With such an innovation, Zydus is not only increasing access to the latest therapies but it is also strengthening the position of manufacturing excellence in advancing healthcare.